A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumor
Eighteen patients with relapsed non-Hodgkin's lym-phoma (NHL) were infused with escalating dose...
Research Funding: None Background:CDX-527 is a bispecific antibody (BsAb) targeting PD-L1 and CD27 t...
BACKGROUND:Smoldering multiple myeloma (SMM) is an indolent disease stage, considered to represent t...
[[abstract]]Background: The IGF signaling pathway has an important role in neoplasia and is associat...
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in pati...
A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients...
BACKGROUND: This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, p...
BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a tetraspanin transmembrane prote...
Summary Background Targeting the cell-surface receptor EphA2, which is highly expressed in some soli...
Abstract Background This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokin...
3556 Background: BIBW 2992 (Tovok) is a potent, irreversible, new generation TKI, an inhibitor of EG...
This study determined the safety, maximum tolerated dose (MTD), pharmacokinetics, and preliminary ef...
Purpose: This multicenter, first-in-human study evaluated safety, tolerability, pharmacokinetics, an...
Background GWN323 is an IgG1 monoclonal antibody (mAb) against the glucocorticoid-induced tumor necr...
Smoldering multiple myeloma (SMM) is an indolent disease stage, considered to represent the transiti...
Eighteen patients with relapsed non-Hodgkin's lym-phoma (NHL) were infused with escalating dose...
Research Funding: None Background:CDX-527 is a bispecific antibody (BsAb) targeting PD-L1 and CD27 t...
BACKGROUND:Smoldering multiple myeloma (SMM) is an indolent disease stage, considered to represent t...
[[abstract]]Background: The IGF signaling pathway has an important role in neoplasia and is associat...
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in pati...
A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients...
BACKGROUND: This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, p...
BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a tetraspanin transmembrane prote...
Summary Background Targeting the cell-surface receptor EphA2, which is highly expressed in some soli...
Abstract Background This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokin...
3556 Background: BIBW 2992 (Tovok) is a potent, irreversible, new generation TKI, an inhibitor of EG...
This study determined the safety, maximum tolerated dose (MTD), pharmacokinetics, and preliminary ef...
Purpose: This multicenter, first-in-human study evaluated safety, tolerability, pharmacokinetics, an...
Background GWN323 is an IgG1 monoclonal antibody (mAb) against the glucocorticoid-induced tumor necr...
Smoldering multiple myeloma (SMM) is an indolent disease stage, considered to represent the transiti...
Eighteen patients with relapsed non-Hodgkin's lym-phoma (NHL) were infused with escalating dose...
Research Funding: None Background:CDX-527 is a bispecific antibody (BsAb) targeting PD-L1 and CD27 t...
BACKGROUND:Smoldering multiple myeloma (SMM) is an indolent disease stage, considered to represent t...